Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
| Revenue (TTM) | $314.85M |
| Gross Profit (TTM) | $270.44M |
| EBITDA | $48.08M |
| Operating Margin | 9.52% |
| Return on Equity | -617.00% |
| Return on Assets | 6.34% |
| Revenue/Share (TTM) | $1.91 |
| Book Value | $0.08 |
| Price-to-Book | 82.13 |
| Price-to-Sales (TTM) | 3.39 |
| EV/Revenue | 3.86 |
| EV/EBITDA | 22.75 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 38.30% |
| Shares Outstanding | $172.64M |
| Float | $163.84M |
| % Insiders | 3.35% |
| % Institutions | 62.29% |
Volatility is currently expanding